Signos, a metabolic health platform focused on helping employees improve their well-being and providing employers with data for informed benefits decisions, has secured $20.0M in Series B funding. The capital will further its work in offering a proactive approach to workforce health, potentially reducing reliance on costly GLP-1 medications.
The company stands out as the first FDA-cleared platform of its kind, leveraging Dexcom’s Stelo CGM and AI-driven guidance. This technology translates real-time glucose data into personalized, actionable recommendations, supporting sustainable weight management and overall better metabolic health for employees.














